Article

Not peer-reviewed version

Cocaine, Amphetamine or Titin - The Culprit behind Dilated Cardiomyopathy: A Case Series of Three Cases and Literature Review

Binay Panjiyar * , Nikita Changlani , Saroj Jha , Safa Kaleem , Grishma Sharma , Sanam Wasim Khan , Mohammed Omar Khan

Posted Date: 17 May 2024

doi: 10.20944/preprints202405.1195.v1

Keywords: cardiology; dilated cardiomyopathy; titin; ischemic cardiomyopathy

Article

Cocaine, Amphetamine or Titin - The Culprit behind Dilated Cardiomyopathy: A Case Series of Three Cases and Literature Review

Binay Kumar Panjiyar [1,*], Nikita Changlani [2], Saroj Kumar Jha [3], Safa Kaleem [4] and Grishma Sharma [5], Sanam Wasim Khan [6], Mohammed Omar Khan [7]

1 Binay Kumar Panjiyar MBBS GCSRT; PGME, Harvard Medical School; ORCID id: 0000-0002-7813-8128; binaypanjiyar1282@hotmail.com
2 Nikita Changlani MS4; Paul L. Foster School of Medicine; 0009-0004-9924-9099; nchangla@ttuhsc.edu
3 Dr. Saroj Kumar Jha, MBBS; Institute of Medicine, Tribhuvan University; jhasaroj13@gmail.com, orcid id: 0000-0002-0433-2788
4 Dr. Safa Kaleem, MBBS; Shadan Institute of Medical Sciences, Hyderabad, India; safakaleem24@gmail.com; ORCID ID- https://orcid.org/0009-0005-9704-818
5 Dr. Grishma Sharma, MBBS; Kathmandu University School of Medical Sciences, Dhulikhel, Nepal, grishmasharma46@gmail.com; ORCID id - https://orcid.org/0000-0002-1705-1299
6 Sanam Wasim Khan, MBBS; sanamhumayun13@gmail.com; CMH Lahore medical college; ORCID id 0009-0003-2136-3396
7 Mohammed Omar Khan, MBBS; omarkhan140294@gmail.com; CMH Multan Institute of Medical Sciences; ORCID id 0009-0004-2616-9821
* Correspondence: Author: Binay Kumar Panjiyar MBBS GCSRT (PGME, Harvard Medical School)

ABSTRACT: Nonischemic dilated cardiomyopathy (DCM) is a complex cardiovascular condition often characterized by genetic pathogenesis. Comprehensive genetic testing has become a crucial aspect of DCM diagnosis and management, offering insights into prognosis and the identification of at-risk individuals. This case series and mini literature review examines the diagnostic and therapeutic dimensions of DCM, emphasizing the role of genetic evaluation. We delve into distinct genetic pathways associated with DCM and their pathogenetic mechanisms, emphasizing the evolving significance of genetic markers, particularly in cases where arrhythmia risk is heightened. The historical reliance on cardiac morphology to subtype cardiomyopathies is being complemented by the identification of genetic variants, further refining DCM subtypes, and aiding in clinical management. The giant sarcomere protein, titin, is a pivotal determinant of cardiomyocyte stiffness and plays a crucial role in cardiac strain sensing. Titin's extensive size and complexity make it susceptible to dysregulation, which has far-reaching consequences in cardiac disorders. This case series with a literature review explores the molecular mechanisms governing titin-based forces in both health and disease. It highlights the influence of isoform diversity and post-translational modifications on myocardial stiffness and contractility. In the context of cardiac diseases, we discuss how titin properties are altered, focusing on changes in titin stiffness and protein quality control. Notably, we address the pathomechanisms associated with truncation in the titin gene (TTN) in human cardiomyopathy, shedding light on potential therapeutic approaches for conditions such as HFpEF and TTN-truncation cardiomyopathy. This comprehensive understanding of DCM and Titin's role in cardiac physiology and pathology provides a solid foundation for addressing cases like that of our patients, who were presented with features of heart failure and arrhythmias. Despite immediate and extensive resuscitative measures, the patient's protracted response to the treatment raised questions about the potential underlying genetic factors contributing to their clinical presentation. These cases underscore the importance of genetic evaluation in unraveling the complexity of cardiomyopathies, ultimately enhancing our ability to manage and treat such challenging cases.

keywords: cardiology; dilated cardiomyopathy; titin; ischemic cardiomyopathy

 doi:10.20944/preprints202405.1195.v1

Case History and Presentation

Case 1:

A 51-year-old Hispanic male patient with heart failure NYHA class II-III presented to our center for a 3-month follow-up with significant improvement of symptoms after guideline-directed medical therapy. The patient denied any history of chest pain, shortness of breath at rest or on exertion, syncope, palpitations, loss of consciousness, or claudication.

He was previously diagnosed with chronic systolic heart failure (ejection fraction improved after single chamber AICD implant), and ischemic cardiomyopathy. There was a history of non-sustained ventricular tachycardia, premature ventricular contractions, and ventricular couplets. Other risk factors for coronary artery disease such as obesity, hypertension, type II diabetes mellitus, and dyslipidemia were also present. He had a history of Quadruple Bypass done 5 years back. He was taking valsartan, furosemide, hydralazine, rosuvastatin, spironolactone aspirin, empagliflozin, omega-3 polyunsaturated fatty acids, and cholecalciferol. He has a family history of myocardial infarction in his mother, congestive heart failure in two brothers and a sister at 57, 54, and 57 years of respectively, diabetes mellitus in his sister, murmur in his 15-year-old daughter, and autism in his son. He is a non-smoker and non-drinker and has no known allergies.

His examination showed a pulse rate of 65 beats/min, blood pressure of 112/75 mmHg, and BMI of 35.2. Heart and lung examinations were within normal limits. Echo showed an ejection fraction of 40-45%, mild mitral regurgitation, and aortic stenosis. A Cardiometabolic Genome test was ordered to evaluate the genetic basis for cardiac arrhythmias. The result showed a heterozygous c.68885_68888dupATAC (p. lle22964TyrfsTer8) likely pathogenic variant in the TTN (NM_001267550.1) gene. This was indicative of titin cardiomyopathy due to the genetic inheritance of a mutation in the TTN gene. In addition, this patient also has ischemic cardiomyopathy due to acquired coronary artery disease.

He was advised to continue the anti-diabetic diet, DASH diet, and as-tolerated exercise. Medications were adjusted to sacubitril-valsartan in place of valsartan. A follow-up echo after 3 months was scheduled.

Case 2:

A 65-year-old Hispanic female patient presented with right-sided chest pain, not precipitated by exertion, every day to every other day; not relieved by paracetamol. She also had shortness of breath on and off and dyspnea on exertion. The patient denied any history of syncope, orthopnea, palpitations, loss of consciousness, dizziness, or claudication.

The patient has a history of tachycardia-mediated cardiomyopathy, systolic heart failure, and pulmonary hypertension. In addition, she had a history of unprovoked acute deep vein thrombosis complicated with acute pulmonary embolism which was treated with catheter-directed thrombolysis. Other risk factors for cardiac disease such as hypertension, type II diabetes mellitus, and obesity were also present. She was taking carvedilol, losartan, omega-3 polyunsaturated fatty acids, polyethylene glycol, and rivaroxaban. She has a family history of myocardial infarction in her brother who died at 60 years of age. She was a non-drinker, an ex-smoker who quit more than a decade ago and has no known allergies.

Her examination showed a pulse rate of 76 beats/min, blood pressure of 109/66 mmHg, and BMI of 39.2. Heart and lung examinations were within normal limits. The Echo showed an ejection fraction of 35-40%. Holter monitor showed normal sinus rhythm, and 2 episodes of non-sustained paroxysmal atrial fibrillation with a rapid ventricular rate; the longest run was 10 seconds at 140 beats/min. ECG performed on the day of examination showed normal sinus rhythm. The Trade Mill test was negative for ischemia. Lexiscan nuclear stress test was planned to evaluate for coronary artery disease and rule out inducible ischemia.

A genome study was requested to evaluate for genetic mutations that may predispose patients to cardiovascular risks. The result showed a heterozygous c.75138_75141del (p. Lys25046Asnfs*8)

 doi:10.20944/preprints202405.1195.v1

likely pathogenic variant in the TTN (NM_001267550.1) gene. This was indicative of titin cardiomyopathy due to the genetic inheritance of a mutation in the TTN gene.

She was advised to continue the anti-diabetic diet and as-tolerated exercise. Medications were adjusted to rosuvastatin in place of atorvastatin. A follow-up was scheduled to review the report of the stress test.

Case 3:

A 48-year-old Hispanic male patient with a history of heart failure (baseline ejection fraction of 15%) presented to our center for a follow-up. The patient denied any history of chest pain, shortness of breath at rest or on exertion, syncope, orthopnea, paroxysmal nocturnal dyspnea, palpitations, loss of consciousness, dizziness, or claudication.

The patient had a history of non-ischemic cardiomyopathy which was treated in line with alcohol-induced cardiomyopathy and ejection fraction improved from 10% to 30%. He also had ventricular tachycardia which was controlled on amiodarone and confirmed by AICD interrogations. Other risk factors for cardiac disease such as hypertension, dyslipidemia with low HDL, obesity, and heavy alcohol abuse before quitting 4 years ago. He is currently on guideline-directed medical therapy including amiodarone, aspirin, carvedilol, rosuvastatin, and spironolactone. He has a family history of hypertension and stroke in his father. He was a non-smoker, consumes beer 1-2 times per week, and has no known allergies.

His examination showed a pulse rate of 66 beats/min, blood pressure of 116/77 mmHg, and BMI of 31.1. Heart and lung examinations were within normal limits. ECG on the day of examination showed normal sinus rhythm. The Echo showed an ejection fraction of 30%. AICD check showed two events of possible supraventricular tachycardia at 180 beats/min, lasting 15 seconds. Cardiac catheterization showed normal coronary arteries.

A genome study was requested to evaluate for genetic mutations that may predispose patients to cardiomyopathy. The result showed a heterozygous c.67495C>T (p. Arg22499Ter) pathogenic variant in the TTN (NM_001267550.1) gene. This was indicative of titin cardiomyopathy due to the genetic inheritance of a mutation in the TTN gene.

He was advised to continue the low carbohydrate diet, DASH diet, and as-tolerated exercise to lose weight. Sacubitril-valsartan was added. A follow-up EKG after 4 months was scheduled.

Discussion:

Introduction to TTN and Dilated Cardiomyopathy:

Titin, encoded by the gene TTN, is a colossal protein that plays a fundamental role in maintaining the structural and functional integrity of the sarcomere, extending from the Z-disk to the M-band (1). The intricate cytoarchitecture of striated muscle, with its precise organization and coordination, is essential for the remarkable contractile properties of these tissues. At the heart of this complexity lies Titin (TTN), an enormous protein that spans the sarcomere from the Z-disk to the M-band, serving as a linchpin in maintaining muscle integrity and function. While TTN's structural role is well-established, its involvement in cardiac pathophysiology, specifically in Dilated Cardiomyopathy (DCM), has emerged as a central focus in cardiovascular research.

TTN is a giant protein, the largest expressed in the heart, with a staggering ≈35,000 amino acids. Its size and the extensive alternative splicing, especially in its I-band region, make it a challenging subject of study. TTN is integral to sarcomere contraction and signaling, acting as a molecular spring, and providing passive force. The specific isoforms of TTN also influence ventricular compliance, adding an additional layer of complexity.

DCM, a condition characterized by dilatation of the left ventricle and impaired systolic function, has multifaceted etiologies. Among these, TTN-truncating variants (TTNtvs) have gained prominence (1). These variants are increasingly recognized as a common genetic cause of DCM, adding to the complexity of understanding the disease. This relationship between TTN and DCM has stirred intense debate regarding the precise mechanisms by which TTNtvs contribute to cardiomyopathy, whether through haploinsufficiency, dominant negative effects, or other mechanisms (1,2).

This review delves into the multifaceted world of TTN and its pivotal role in DCM pathogenesis. It explores the evolving understanding of TTN's function, genetic variations, and clinical implications in DCM, shedding light on the complex interplay between this giant molecule and cardiac health.

Role of TTN in Dilated Cardiomyopathy:

Dilated Cardiomyopathy (DCM) is a complex cardiovascular disorder characterized by the enlargement of the left ventricle and impaired systolic function, resulting in heart failure and arrhythmias. While the etiology of DCM is diverse, one genetic contributor that has garnered significant attention is truncations of the titin gene (TTN), as demonstrated in the pivotal study by Herman et al. in 2012 (2).

Titin, the largest known protein, plays a central role in maintaining sarcomere integrity and function. It functions as a molecular spring, providing passive tension and regulating sarcomere contraction. Titin is encoded by the TTN gene, which contains an astonishing 363 coding exons. The sheer size of this gene, with the resulting vast potential for genetic variation, has made it a subject of intense scrutiny in the context of DCM.

Herman et al. (2) identified that truncating mutations of the TTN gene were associated with DCM. Truncating mutations result in the premature termination of protein synthesis, leading to a truncated titin protein (TTNtv) or its absence. The study revealed that these TTNtv-bearing individuals have a significantly increased risk of DCM.

One of the key findings of this study was the high prevalence of TTNtv in patients with idiopathic or familial DCM. Approximately 25% of familial cases of idiopathic DCM and 18% of sporadic cases were found to carry TTNtv (2). These statistics underscore the significance of TTNtv as a genetic contributor to DCM, especially in cases with a familial predisposition.

Notably, TTNtv was observed to be an independent risk factor for DCM, with a fourfold increase in the odds of developing the disease. This highlights the critical role of TTN in maintaining normal cardiac structure and function. The study also emphasized that TTNtv was the most common genetic cause of DCM identified to date.

The consequences of TTNtv in DCM extend beyond familial cases. The study revealed that TTNtv was also present in sporadic DCM cases. This suggests that TTNtv may not only contribute to familial DCM but also play a significant role in the broader DCM population, emphasizing the clinical relevance of these findings.

The mechanisms underlying how TTNtv lead to DCM have been a subject of ongoing debate and research. One hypothesis is the haploinsufficiency model, where the loss of one functional TTN allele leads to insufficient titin protein production, ultimately compromising sarcomere function and contributing to DCM. Another possibility is the "poison peptide" hypothesis, where the truncated titin protein itself, encoded by the TTNtv-bearing allele, may interfere with sarcomere function and integrity.

Understanding the functional consequences of TTNtv has been crucial. Herman et al. noted that TTNtv-bearing individuals exhibited variable expressivity of DCM, suggesting that factors beyond genetics contribute to the development and progression of the disease. It was also observed that TTNtv were more frequently associated with a milder form of DCM, indicating that factors such as additional genetic modifiers or environmental influences may modulate the severity of the disease.

In summary, the study by Herman et al. in 2012 significantly advanced our understanding of the role of TTN in Dilated Cardiomyopathy. TTNtv, truncations of the TTN gene, were identified as a common genetic cause of DCM, present in both familial and sporadic cases. The study highlighted the complexity of DCM and the multifaceted factors that influence disease development. These findings underscore the importance of considering genetic factors, such as TTNtv, in the clinical evaluation and management of DCM patients, paving the way for further research into the precise mechanisms by which TTNtv contribute to this complex cardiovascular disorder.

The Controversies Surrounding TTNtvs in DCM

Haploinsufficiency vs. Poison Peptide:

The discovery of titin-truncating variants (TTNtvs) as a common genetic cause of Dilated Cardiomyopathy (DCM) has sparked intense research and debate within the scientific community. While TTNtvs play a significant role in DCM, several controversies and challenges have emerged, which are highlighted in the seminal studies by Roberts et al. (2015) and Schafer et al. (2015).

One of the key controversies surrounding TTNtvs in DCM pertains to their penetrance and expressivity. Roberts et al. conducted a comprehensive analysis, integrating allelic, transcriptional, and phenotypic data, to unravel the complex effects of TTNtvs. They observed that TTNtvs are not solely deterministic of DCM. Instead, they found a broad range of clinical outcomes in TTNtv carriers, from asymptomatic individuals to those with severe DCM. This observation challenges the notion that TTNtvs directly translate to a uniform DCM phenotype. The interplay of genetic and environmental factors, as well as additional genetic modifiers, likely contributes to the variable expressivity of TTNtvs in DCM. This complexity has led to ongoing discussions about how to predict the clinical trajectory of TTNtv carriers and the implications for genetic counseling and clinical management.

Another contentious issue revolves around the distinction between TTNtvs as pathogenic or benign variations. Schafer et al. (4) delved into this matter by examining TTNtvs in both disease cohorts and the general population. They discovered that TTNtvs were not exclusive to DCM patients but were also present in individuals without cardiac disease. This observation challenges the traditional dichotomy of pathogenic and non-pathogenic variants. It suggests that TTNtvs may not always result in clinical manifestations of DCM. Therefore, determining the clinical significance of TTNtvs becomes a complex task, raising questions about the necessity and appropriateness of genetic testing in asymptomatic individuals carrying TTNtvs. The potential implications of labeling TTNtvs as pathogenic are not to be taken lightly, as it could lead to unnecessary psychological distress and overtreatment.

Furthermore, there is an ongoing debate regarding the precise mechanisms by which TTNtvs contribute to DCM. While haploinsufficiency, where the loss of one functional TTN allele leads to insufficient titin protein production, is a leading hypothesis, the exact pathophysiology remains elusive. The "poison peptide" hypothesis, suggesting that the truncated titin protein itself interferes with sarcomere function, continues to be investigated. Understanding these mechanisms is essential for the development of targeted therapies. Research efforts are underway to decipher the complex interactions between TTNtvs and other genetic and environmental factors that ultimately lead to DCM.

In summary, the controversies surrounding TTNtvs in DCM highlight the intricate nature of this genetic contribution to cardiac disease. Penetrance, expressivity, clinical significance, and the precise mechanisms remain subject to intense scrutiny and ongoing research. While TTNtvs are a significant factor in DCM, the multifaceted nature of this genetic variant underscores the need for a comprehensive and individualized approach to genetic counseling and clinical management for affected individuals and their families. As the field of genomics and cardiology continues to advance, these controversies will be increasingly elucidated, providing a clearer picture of TTNtvs' role in DCM and their clinical implications.

Detection and Clinical Implications of TTN Truncating Variants (TTNtvs) in Dilated Cardiomyopathy (DCM):

Dilated Cardiomyopathy (DCM) is a complex and heterogeneous cardiac condition characterized by the dilation and impaired function of the left ventricle, ultimately leading to heart failure. It is widely recognized that genetic factors play a substantial role in the pathogenesis of DCM, and in recent years, one genetic element has garnered significant attention - Truncating Variants (TTNtvs) in the TTN gene (5). The detection of TTNtvs in the context of DCM primarily relies on advanced genetic testing methods. Genetic testing, as highlighted in the reference "Genetic Evaluation of Cardiomyopathy: A Clinical Practice Resource of the American College of Medical

 doi:10.20944/preprints202405.1195.v1

Genetics and Genomics (ACMG)," has become an indispensable tool for clinicians in assessing and managing DCM patients. This process typically begins with a comprehensive evaluation of a patient's family history and clinical symptoms, laying the foundation for genetic testing.

Genetic testing for DCM involves the examination of a panel of genes known to be associated with this cardiac condition. Among these genes, TTN stands out prominently due to the relatively high prevalence of TTNtvs in DCM patients. The advent of Next-Generation Sequencing (NGS) technologies, including whole-exome sequencing (WES) and whole-genome sequencing (WGS), has brought a paradigm shift in the detection of genetic variants such as TTNtvs. These state-of-the-art techniques enable the simultaneous analysis of numerous genes, making the process highly efficient for identifying potentially pathogenic variants, including TTNtvs. Once the data is generated, it undergoes a meticulous interpretation and reporting process. Laboratories scrutinize the genetic information to pinpoint potential pathogenic variants, such as TTNtvs, which are then reported back to the attending clinician.

However, the journey doesn't conclude here; the importance of genetic counseling cannot be overstated. Genetic counseling plays an instrumental role in helping individuals and their families comprehend the implications of TTNtvs. It provides invaluable insights into the inheritance patterns, clinical significance, and the potential impact of these variants on disease risk. This step is pivotal in ensuring that individuals are well-informed about their genetic makeup and can make educated decisions regarding their health, family planning, and lifestyle choices.

The clinical implications of TTNtvs in DCM are multifaceted. One of the most intriguing aspects of these variants is their variable penetrance and expressivity. Unlike some genetic mutations that invariably lead to disease, TTNtvs exhibit a wide spectrum of effects. Some carriers remain entirely asymptomatic, while others develop severe heart failure. This inherent variability poses a significant challenge in predicting the clinical course for TTNtv carriers, underlining the complexity of DCM.

For clinicians and genetic counselors, the identification of TTNtvs in DCM patients or asymptomatic carriers within affected families carries several vital clinical implications. Firstly, it enables risk assessment, aiding in the determination of the need for closer monitoring, lifestyle modifications, and potential therapeutic interventions. Secondly, it emphasizes the importance of genetic counseling, providing carriers with the knowledge they need to navigate the potential consequences of TTNtvs.

Furthermore, it encourages a more personalized approach to treatment. While specific therapies targeting TTNtvs are still under investigation, carriers can potentially benefit from traditional heart failure treatments and lifestyle adjustments. This personalized approach may significantly improve the quality of life for affected individuals.

In conclusion, the detection of TTNtvs in DCM through genetic testing is pivotal for understanding the genetic underpinnings of this condition. It not only aids in early diagnosis but also facilitates risk stratification within families, helping to identify asymptomatic carriers who may require monitoring and preventive measures. Beyond its diagnostic value, genetic testing, particularly for TTNtvs, paves the way for the future of precision medicine. As the field of genomes advances, the knowledge of genetic variants like TTNtvs is essential for their potential application in tailored treatments, offering hope for more effective DCM management in the years to come.

Mechanistic Insights into TTN Truncating Variants (TTNtvs) in Dilated Cardiomyopathy (DCM) and Clinical Manifestations:

Dilated Cardiomyopathy (DCM) is a complex and heterogeneous cardiovascular disorder characterized by the progressive dilation of the left ventricle and impaired contractility, often resulting in heart failure. Recent research, as highlighted in several studies, including "Titin Truncating Variants in Dilated Cardiomyopathy – Prevalence and Genotype-Phenotype Correlations" (6) and "Prevalence and Clinical Impact of Titin Truncating Variants in Dilated Cardiomyopathy," (7) has unveiled a critical genetic factor implicated in the pathogenesis of DCM—Truncating Variants (TTNtvs) in the TTN gene. Understanding the mechanistic insights into TTNtvs and their clinical manifestations in DCM is pivotal for advancing the diagnosis and treatment of this condition.

Mechanistic Insights:

TTN is a colossal sarcomere protein, aptly dubbed the "molecular spring." It plays a fundamental role in maintaining sarcomere stability and contributes to muscle elasticity. When TTNtvs occur, they lead to the truncation or loss of essential functional domains in this protein, particularly in the A-band region. The A-band houses the molecular motors of muscle contraction, including myosin. TTN acts as a blueprint, providing the structural and functional framework for myosin and other sarcomere proteins to work harmoniously. In the presence of TTNtvs, this harmonious synergy is disrupted.

One of the pivotal mechanistic insights into TTNtvs is their impact on sarcomere assembly and stability. TTNtvs disrupt the formation and organization of sarcomeres, leading to abnormal muscle structure. This disruption ultimately results in the hallmark features of DCM, such as ventricular dilation and decreased contractile function. The loss of TTN's structural integrity due to these variants can impair muscle contraction, contributing to the inefficient pumping of blood by the heart.

Moreover, TTNtvs trigger a cellular stress response in cardiomyocytes. The unfolded protein response and cellular signaling pathways are activated as the cells attempt to cope with the mutated and misfolded TTN protein. This ongoing stress can lead to cell death and fibrosis. The reference "Association of Fibrosis with Mortality and Sudden Cardiac Death in Patients with Nonischemic Dilated Cardiomyopathy" (8) emphasizes the clinical significance of fibrosis in DCM. Fibrosis is a common histological feature in DCM patients with TTNtvs and is associated with an increased risk of adverse outcomes, including sudden cardiac death.

Clinical Manifestations:

The clinical manifestations of TTNtvs in DCM are highly variable, which adds an additional layer of complexity to this condition. Notably, not all carriers of TTNtvs develop DCM. Some remain asymptomatic throughout their lives, while others present with a broad spectrum of symptoms.

The clinical heterogeneity associated with TTNtvs is partly explained by genotype-phenotype correlations. Certain specific TTNtv locations and types are more likely to result in DCM. However, these correlations are not absolute, and the clinical presentation may vary widely even within families carrying the same TTNtv. This inter- and intrafamilial variability underscores the multifactorial nature of DCM.

The long-term prognosis of DCM patients with TTNtvs is another facet of clinical significance. "Long-Term Prognostic Impact of Therapeutic Strategies in Patients with Idiopathic Dilated Cardiomyopathy" (9) highlights that while therapeutic strategies have improved over the years, DCM with TTNtvs remains a challenging condition to manage. Some patients with TTNtvs experience progressive heart failure, leading to adverse outcomes, while others may respond well to treatment and have a relatively favorable prognosis.

In conclusion, TTNtvs in DCM provide a fascinating insight into the intricate mechanisms underlying the disease. These genetic variants disrupt sarcomere assembly, trigger cellular stress responses, and contribute to the characteristic clinical manifestations of DCM. Understanding the variable clinical outcomes associated with TTNtvs is crucial for risk stratification, genetic counseling, and tailoring treatment approaches for affected individuals. Further research is essential to unravel the precise mechanisms of TTNtvs and develop targeted therapies to improve the prognosis of DCM patients with these variants.

Elaborating on Genetic Aspects and Molecular Mechanisms of TTN Truncating Variants (TTNtvs) in Dilated Cardiomyopathy (DCM):

Understanding the genetic underpinnings and molecular mechanisms of TTNtvs in DCM is crucial for unraveling the complexity of this condition. Two significant studies, "Prediction of Sarcomere Mutations in Subclinical Hypertrophic Cardiomyopathy"(10) and "Antisense-Mediated Exon Skipping: A Therapeutic Strategy for Titin-Based Dilated Cardiomyopathy,"(11) shed light on these aspects.

Genetic Aspects:

Prediction of Sarcomere Mutations in Subclinical Hypertrophic Cardiomyopathy focuses on the prediction of sarcomere mutations in individuals with subclinical hypertrophic cardiomyopathy (HCM). Sarcomere mutations, including TTNtvs, are known to underlie HCM, a condition characterized by thickening of the heart muscle. This study highlights the potential genetic overlap between HCM and DCM, emphasizing the heterogeneity of TTNtvs. It implies that individuals with TTNtvs may exhibit different clinical manifestations depending on genetic modifiers and environmental factors.

Elaborating on Molecular Mechanisms:

Antisense-Mediated Exon Skipping: A Therapeutic Strategy for Titin-Based Dilated Cardiomyopathy delves into a potential therapeutic approach for TTN-based DCM. TTN is one of the largest known human proteins, with a complex structure comprising multiple exons. TTNtvs often lead to the mis-splicing of TTN exons, resulting in a dysfunctional protein.

The study explores the concept of antisense-mediated exon skipping, a strategy that aims to correct the aberrant splicing caused by TTNtvs. This innovative approach involves designing antisense oligonucleotides (ASOs) to target specific exons affected by TTNtvs. By modulating splicing, ASOs can potentially restore the correct reading frame and functional integrity of the truncated TTN protein.

In summary, TTNtvs in DCM are genetically heterogeneous, and their clinical manifestations can extend beyond DCM to conditions like HCM. Molecular mechanisms involve the mis-splicing of TTN exons, leading to dysfunctional protein products. The therapeutic strategy of antisense-mediated exon skipping holds promise as a potential treatment for TTN-based DCM by restoring the correct splicing pattern and, consequently, cardiac function. These insights shed light on the intricate genetic and molecular landscape of TTNtvs in DCM and open doors to innovative therapeutic approaches for this challenging condition.

Current Diagnostic and Therapeutic Strategies for Dilated Cardiomyopathy (DCM):

Dilated cardiomyopathy (DCM) is a complex and genetically heterogeneous cardiac disorder characterized by the dilation of the left ventricle and systolic dysfunction. Accurate diagnosis and effective management of this condition requires a comprehensive understanding of its genetic underpinnings alongside clinical and therapeutic aspects. This section provides a detailed analysis of the current diagnostic and therapeutic strategies for DCM, incorporating lifestyle recommendations and preventive measures. It emphasizes the need for a holistic approach to address this multifaceted condition.

Diagnostic Strategies: Precise diagnosis forms the cornerstone of DCM management. This process involves a multifaceted approach that encompasses clinical evaluations, advanced imaging techniques, and genetic analysis.

Clinical Assessment: A comprehensive clinical assessment is indispensable for DCM diagnosis. Patients typically present with symptoms of heart failure, including dyspnea, fatigue, and edema. However, these symptoms are nonspecific and may overlap with other cardiac conditions, necessitating careful differentiation. The patient's clinical history, physical examination, and the presence of a family history of DCM play pivotal roles in the diagnostic process.

Imaging Modalities: Echocardiography stands as the primary imaging modality for cardiac assessment and remains pivotal in evaluating cardiac structure and function. DCM patients often exhibit left ventricular dilation and reduced ejection fraction. Moreover, as highlighted by Towbin et al., a subset of DCM cases is associated with left ventricular non-compaction (LVNC) (12), a condition detectable through echocardiography. Cardiac magnetic resonance imaging (MRI) offers enhanced tissue characterization, particularly valuable for distinguishing DCM from other cardiomyopathies.

Genetic Testing: The genetic aspect of DCM, underscored by Hershberger et al. (13), is gaining prominence. Genetic testing can identify pathogenic mutations in genes such as TTN, which is crucial

 doi:10.20944/preprints202405.1195.v1

for genetic counseling and family screening. A profound understanding of the genetic basis of DCM is pivotal, as it significantly influences disease progression, prognosis, and treatment decisions.

Therapeutic Strategies: The management of DCM is multifaceted and aims at alleviating symptoms, enhancing the patient's quality of life, and retarding disease progression. The choice of therapeutic strategies is predicated on individual patient characteristics.

Pharmacological Interventions: Pharmacotherapy constitutes the foundation of DCM treatment. Medications such as angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, and mineralocorticoid receptor antagonists have demonstrated efficacy in mitigating cardiac remodeling, improving heart function, and alleviating symptoms. Tailored medication regimens are crucial, considering the heterogeneity of DCM presentations.

Device-Based Therapies: For individuals at higher risk of life-threatening arrhythmias, implantable cardioverter-defibrillators (ICDs) are indicated, as referenced in the section on arrhythmia management (14). ICDs can detect and terminate ventricular arrhythmias, providing a vital safety net for DCM patients. Cardiac resynchronization therapy (CRT) may also be recommended for those with conduction abnormalities, further optimizing cardiac function.

Surgical Interventions: In advanced cases, heart transplantation represents the definitive treatment option. Ventricular assist devices (VADs) have emerged as a bridge to transplantation or destination therapy for select DCM patients. These devices significantly enhance the patient's quality of life and may be the only recourse for those awaiting a suitable donor organ.

Lifestyle Recommendations and Preventive Measures: In the management of DCM, lifestyle recommendations and preventive measures are essential components.

Dietary Modifications: Patients are advised to reduce salt intake and adhere to fluid restriction guidelines. Alcohol consumption should be minimized or abstained from entirely, as it can exacerbate cardiomyopathy.

Physical Activity: Regular physical activity, under the supervision of healthcare providers, is encouraged to maintain cardiovascular fitness. However, excessive physical strain should be avoided, as it can exacerbate the condition.

Genetic Counseling and Testing: Given the genetic nature of DCM, genetic counseling and testing are paramount. Identifying at-risk family members is essential for early intervention and surveillance. Periodic echocardiography is recommended to detect DCM in its asymptomatic or early stages, facilitating timely therapeutic interventions.

In summary, DCM is a complex and genetically diverse condition with a significant genetic component. The diagnostic approach integrates clinical evaluations, advanced imaging, and genetic insights. Treatment strategies encompass pharmacological, device-based, and surgical interventions tailored to individual patient needs. Lifestyle recommendations and preventive measures are vital aspects of DCM management, with a particular focus on genetic counseling and early detection in at-risk family members. The comprehensive approach presented here underscores the multifaceted nature of DCM and emphasizes the need for an interdisciplinary approach to enhance patient outcomes.

Conclusion

In conclusion, the relationship between Titin (TTN) and Dilated Cardiomyopathy (DCM) is complex and pivotal in cardiovascular research. TTN-truncating variants (TTNtvs) are a common cause of DCM, contributing to a significant proportion of cases. While the precise mechanisms through which TTNtvs lead to DCM are still a subject of debate, they have a substantial impact on heart health.

Genetic testing for TTNtvs plays a crucial role in identifying individuals at risk and guiding clinical management. The diverse clinical manifestations of DCM, ranging from heart failure to arrhythmias, necessitate early detection and personalized care. Understanding the inheritance patterns of TTNtvs is essential for familial screening and genetic counseling.

Current management strategies for DCM encompass established medical therapies, lifestyle recommendations, and preventive measures. Arrhythmia management, particularly for genetic DCM patients, emphasizes the importance of implantable cardioverter-defibrillators (ICDs) and tailored approaches for specific patient subgroups.

As we continue to unravel the intricacies of TTN and DCM, this field holds promise for advancing our understanding of cardiac diseases. Translational efforts, from genetic discoveries to targeted therapies, offer hope for more personalized patient care. The road to understanding TTN and DCM is ongoing, with exciting prospects for the future.

In summary, this discussion highlights the significance of TTN in DCM and its broader implications. The challenges and controversies surrounding TTNtvs in DCM should motivate further research to refine diagnostics and develop tailored therapeutic approaches for this heterogeneous condition. Our collective efforts in TTN and DCM research aim to improve patient outcomes and enhance our understanding of cardiomyopathies.

References

1. Clark K.A., McElhinny A.S., Beckerle M.C., Gregorio C.C. (2002) Striated muscle cytoarchitecture: an intricate web of form and function. Annu Rev Cell Dev Biol. 18:637-706.
2. Herman D.S., Lam L., Taylor M.R., et al. (2012) Truncations of titin causing dilated cardiomyopathy. N Engl J Med. 366(7):619-628.
3. Roberts A.M., Ware J.S., Herman D.S., et al. (2015) Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease. Sci Transl Med. 7(270):270ra6.
4. Schafer S., de Marvao A., Adami E., et al. (2015) Titin-truncating variants affect heart function in disease cohorts and the general population. Nat Genet. 49(1):46-53.
5. Hershberger R.E., Givertz M.M., Ho C.Y., et al. (2018) Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 20(9):899-909.
6. Franaszczyk M., Chmielewski P., Truszkowska G., et al. (2017) Titin truncating variants in dilated cardiomyopathy – prevalence and genotype-phenotype correlations. PLoS One. 12(3): e0169007.
7. Roberts A.M., Ware J.S., Herman D.S., et al. (2015) Prevalence and clinical impact of titin truncating variants in dilated cardiomyopathy. Circ Genom Precis Med. 8(1):107-114.
8. Gulati A., Jabbour A., Ismail T.F., et al. (2013) Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA. 309(9):896-908.
9. Merlo M., Pivetta A., Pinamonti B., et al. (2017) Long-term prognostic impact of therapeutic strategies in patients with idiopathic dilated cardiomyopathy: changing mortality over the last 30 years. Eur J Heart Fail. 19(5):524-531.
10. Captur G., Lopes L.R., Mohun T.J., et al. (2017) Prediction of sarcomere mutations in subclinical hypertrophic cardiomyopathy. Circ Cardiovasc Imaging. 10(5): e005516.
11. Gramlich M., Pane L.S., Zhou Q., et al. (2015) Antisense-mediated exon skipping: a therapeutic strategy for titin-based dilated cardiomyopathy. EMBO Mol Med. 7(5):562-576.
12. Towbin J.A., Lorts A., Jefferies J.L. (2015) Left ventricular non-compaction cardiomyopathy. Lancet. 386(9995):813-825.
13. Hershberger R.E., Hedges D.J., Morales A. (2013) Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol. 10(9):531-547.
14. Cadrin-Tourigny J., Bosman L.P., Nozza A., et al. (2020) A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. Eur Heart J. 41(33):3178-3187.